Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors

Sorafenib has substantial clinical activity as third- or fourth-line treatment of imatinib- and sunitinib-resistant gastrointestinal stromal tumors (GIST). Because sorafenib targets both angiogenesis-related kinases (VEGFR) and the pathogenetic kinases found in GIST (KIT or PDGFRA), the molecular ba...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Heinrich, Michael C., Marino-Enriquez, Adrian, Presnell, Ajia, Donsky, Rachel S., Griffith, Diana J., McKinley, Arin, Patterson, Janice, Taguchi, Takahiro, Liang, Cher-Wei, Fletcher, Jonathan A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3992122/
https://ncbi.nlm.nih.gov/pubmed/22665524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-12-0223
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares